콘텐츠 바로가기
로그인
컨텐츠

Category Open

Resources

tutorial

Collection of research papers and materials on development issues

home

Resources
Industry and Technology General

Print

Korea, the pharmaceutical industry and non-commercial use in the TRIPS agreement

Related Document
Frame of Image
  • Korea, the pharmaceutical industry and non-commercial use in the TRIPS agreement
  • Shanker, Daya
  • University of Wollongong


link
Title Korea, the pharmaceutical industry and non-commercial use in the TRIPS agreement
Similar Titles
Material Type Reports
Author(English)

Shanker, Daya

Publisher

University of Wollongong

Date 2003-12
Series Title; No Economics Working Papers / 03-15
Pages 40
Subject Country South Korea(Asia and Pacific)
Language English
File Type Link
Subject Industry and Technology < General
Holding University of Wollongong

Abstract

In 2002, a number of associations requested the Korean Patent Office to issue a compulsory license for the manufacture of a drug under the Korean patent provision which permits the issue of compulsory licensing for public non-commercial use. This provision in the Korean patent act was introduced in 1995 ostensibly to comply with Article 31 of the TRIPS Agreement which permits the issue of compulsory licenses without prior consultations with the patent holder. In a change of strategy, the objection to the issue of a compulsory license for the drug, Gleevec, was filed not by the patent holder or by PhRMA, the association and lobby group of the pharmaceutical industry, but by certain individuals claiming to have legal expertise, and sympathizers of the pharmaceutical industry. The objection raised was based on the concept of legitimate expectation, a concept not applicable in the case of the TRIPS Agreement. The objections raised do not appear to be supported by a legal argument and appear to be arbitrary in nature. In addition, they appear to reflect PhRMA’s aims of curtailing the flexibility inherent in the TRIPS Agreement.